PMID- 1689375
OWN - NLM
STAT- MEDLINE
DCOM- 19900322
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 54
IP  - 3
DP  - 1990 Mar
TI  - Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine 
      accumulation in the striatum and nucleus accumbens.
PG  - 1062-7
AB  - The effect of the racemic mixture of 3,4-methylenedioxymethamphetamine (MDMA) on 
      the synthesis of dopamine in the terminals of nigrostriatal and mesolimbic 
      neurons was estimated by measuring the accumulation of 3,4-dihydroxyphenylalanine 
      (DOPA) in the striatum and nucleus accumbens 30 min following the administration 
      of the L-aromatic amino acid decarboxylase inhibitor, 3-hydroxybenzylhydrazine. 
      MDMA produced an increase in DOPA accumulation in the striatum which was greater 
      in magnitude and longer in duration than that in the nucleus accumbens. Although 
      the concentrations of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in 
      both the striatum and nucleus accumbens were reduced 3 h following an injection 
      of MDMA (20 mg/kg), 5-HT and 5-HIAA concentrations were significantly reduced 
      only in the striatum 7 days after the administration of MDMA. Pretreatment with a 
      5-HT2 antagonist, ketanserin, significantly attenuated the reduction in 5-HT 
      concentration in the striatum 3 h following MDMA administration and completely 
      blocked 5-HT depletion at 7 days post administration. Moreover, ketanserin 
      completely blocked MDMA-induced DOPA accumulation in the striatum. The results 
      obtained in these studies suggest that MDMA activates nigrostriatal dopaminergic 
      pathways via 5-HT2 receptors. In addition, these data are supportive of the 
      hypothesis that dopamine plays a role in MDMA-induced 5-HT depletion.
FAU - Nash, J F
AU  - Nash JF
AD  - Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio.
FAU - Meltzer, H Y
AU  - Meltzer HY
FAU - Gudelsky, G A
AU  - Gudelsky GA
LA  - eng
GR  - MH 41594/MH/NIMH NIH HHS/United States
GR  - MH 41684/MH/NIMH NIH HHS/United States
GR  - MH 47808/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Amphetamines)
RN  - 0 (Serotonin Antagonists)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - 63-84-3 (Dihydroxyphenylalanine)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/*pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Corpus Striatum/*metabolism
MH  - Dihydroxyphenylalanine/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Ketanserin/pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Nucleus Accumbens/*metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Septal Nuclei/*metabolism
MH  - Serotonin/metabolism
MH  - Serotonin Antagonists/pharmacology
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1111/j.1471-4159.1990.tb02358.x [doi]
PST - ppublish
SO  - J Neurochem. 1990 Mar;54(3):1062-7. doi: 10.1111/j.1471-4159.1990.tb02358.x.